

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS	13	SEP 27	STANDARDS will no longer be available on STN
NEWS	14	SEP 27	SWETSCAN will no longer be available on STN
NEWS	15	SEP 30	STN downtime scheduled October 2-3, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:25:26 ON 01 OCT 2004

=> file caplus uspatful japio europatful medline biosis embase scisearch		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:26:05 ON 01 OCT 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:26:05 ON 01 OCT 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:26:05 ON 01 OCT 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 17:26:05 ON 01 OCT 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 17:26:05 ON 01 OCT 2004

FILE 'BIOSIS' ENTERED AT 17:26:05 ON 01 OCT 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 17:26:05 ON 01 OCT 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:26:05 ON 01 OCT 2004  
Copyright (c) 2004 The Thomson Corporation.

=> s (accomodative amplitude) or presbyopia  
L1 3182 (ACCOMODATIVE AMPLITUDE) OR PRESBYOPIA

=> s l1 and (break? or disrupt?) and (bonds or (disulfide bonds))  
L2 30 L1 AND (BREAK? OR DISRUPT?) AND (BONDS OR (DISULFIDE BONDS))

=> s l2 and glutathione  
L3 7 L2 AND GLUTATHIONE

=> s l3 and (energy or electromagnetic or sonic or particle or heat)  
L4 6 L3 AND (ENERGY OR ELECTROMAGNETIC OR SONIC OR PARTICLE OR HEAT)

=> d l4 1-6 ibib abs

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:616201 CAPLUS  
DOCUMENT NUMBER: 137:174935  
TITLE: **Presbyopia** treatment by lens alteration  
INVENTOR(S): Till, Jonathan S.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 6 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110549	A1	20020815	US 2002-50879	20020118
WO 2002056804	A2	20020725	WO 2002-US1404	20020118
WO 2002056804	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370237 A2 20031217 EP 2002-709084 20020118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-262423P P 20010119  
WO 2002-US1404 W 20020118

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of **presbyopia** as well as treats it. By **breaking** and/or preventing the formation of **bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule. Biol. acceptable compds. comprise **glutathione** or thiols and enzymes such as **glutathione** S-transferase or thiol reductase can **break disulfide bonds**.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:142552 CAPLUS

DOCUMENT NUMBER: 136:178019

TITLE: **Presbyopia** treatment by lens alteration with reducing agents

INVENTOR(S): Till, Jonathan S.

PATENT ASSIGNEE(S): Refocus, LLC, USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013863	A2	20020221	WO 2001-US25576	20010816
WO 2002013863	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001083386 A5 20020225 AU 2001-83386 20010816

US 2002025311 A1 20020228 US 2001-930287 20010816

PRIORITY APPLN. INFO.: US 2000-225659P P 20000816  
WO 2001-US25576 W 20010816

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By **breaking bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

L4 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2004:41451 USPATFULL  
 TITLE: Keratinocyte growth factor-2  
 INVENTOR(S): Ruben, Steven M., Brookeville, MD, United States  
 Jimenez, Pablo, Chatham, NJ, United States  
 Duan, D. Roxanne, Gaithersburg, MD, United States  
 Rampy, Mark A., Montgomery Village, MD, United States  
 Mendrick, Donna, Mount Airy, MD, United States  
 Zhang, Jun, San Diego, CA, United States  
 NI, Jian, Germantown, MD, United States  
 Moore, Paul A., North Bethesda, MD, United States  
 Coleman, Timothy A., Gaithersburg, MD, United States  
 Gruber, Joachim R., Dallas, TX, United States  
 Dillon, Patrick J., Carlsbad, CA, United States  
 Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693077	B1	20040217
APPLICATION INFO.:	US 2000-610651		20000630 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-345373, filed on 1 Jul 1999 Continuation of Ser. No. US 1998-23082, filed on 13 Feb 1998, now patented, Pat. No. US 6077692 Continuation-in-part of Ser. No. US 1997-910875, filed on 13 Aug 1997 Continuation-in-part of Ser. No. US 1997-862432, filed on 23 May 1997 Division of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995 Continuation-in-part of Ser. No. US 610651 Continuation-in-part of Ser. No. US 1996-696135, filed on 13 Aug 1996 Continuation-in-part of Ser. No. US 1995-461195, filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205417P	20000519 (60)
	US 2000-198322P	20000419 (60)
	US 1999-171677P	19991222 (60)
	US 1999-163375P	19991103 (60)
	US 1999-149935P	19990819 (60)
	US 1999-148628P	19990812 (60)
	US 1999-144024P	19990715 (60)
	US 1999-143648P	19990714 (60)
	US 1999-142343P	19990702 (60)
	US 1997-39045P	19970228 (60)
	US 1997-55561P	19970813 (60)
	US 1996-23852P	19960813 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Saoud, Christine J.  
 LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.  
 NUMBER OF CLAIMS: 48  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 80 Drawing Figure(s); 64 Drawing Page(s)  
 LINE COUNT: 16222  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter

referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:265887 USPATFULL  
TITLE: Keratinocyte growth factor-2  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Jimenez, Pablo, Chatham, NJ, UNITED STATES  
Duan, Roxanne D., Bethesda, MD, UNITED STATES  
Rampy, Mark A., Montgomery Village, MD, UNITED STATES  
Mendrick, Donna, Mount Airy, MD, UNITED STATES  
Zhang, Jun, Bethesda, MD, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES  
Gruber, Joachim R., Elizabethtown, KY, UNITED STATES  
Dillon, Patrick J., Carlsbad, CA, UNITED STATES  
Gentz, Reiner L., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186904	A1	20031002
APPLICATION INFO.:	US 2002-35212	A1	20020104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-259853P	20010108 (60)
	US 2001-286368P	20010426 (60)
	US 2001-331168P	20011109 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934

NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 64 Drawing Page(s)  
LINE COUNT: 17177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:205862 USPATFULL  
TITLE: Presbyopia treatment by lens alteration  
INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002110549 A1 20020815  
APPLICATION INFO.: US 2002-50879 A1 20020118 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-262423P 20010119 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,  
WASHINGTON, DC, 20005  
NUMBER OF CLAIMS: 33  
EXEMPLARY CLAIM: 1  
LINE COUNT: 515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of **presbyopia** as well as treats it. By **breaking** and/or preventing the formation of **bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 6 USPATFULL on STN  
ACCESSION NUMBER: 2002:42947 USPATFULL  
TITLE: **Presbyopia** treatment by lens alteration  
INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002025311 A1 20020228  
APPLICATION INFO.: US 2001-930287 A1 20010816 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-225659P 20000816 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,  
WASHINGTON, DC, 20005  
NUMBER OF CLAIMS: 33  
EXEMPLARY CLAIM: 1  
LINE COUNT: 472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By **breaking bonds** that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.